Latest Novaremed News & Updates

See the latest news and media coverage for Novaremed. We track all announcements, press releases, and industry mentions in real time, all in one place.

Novaremed

Clinical-stage biopharmaceutical company developing non-opioid pain therapies

novaremed.com

Headquarters: Basel, Switzerland
Founded year: 2017
Company type: Private company
Number of employees: 6–10
Industry: Pharmaceuticals

Last updated July 21, 2022

Latest news about Novaremed

In short: Novaremed completed Phase 2b trial visits for diabetic neuropathy pain; topline results were expected in November 2025.

Company announcements

July 21, 2022 Novaremed

Novaremed enters license agreement with NeuroFront for NRD.E1

NeuroFront gains option for exclusive rights in Greater China and Singapore. Novaremed receives over USD 130 million in fees, milestones, and royalties.

September 7, 2021 Novaremed

Novaremed acquires Metys Pharmaceuticals

The acquisition adds two non-opioid projects for CIPN and PDPN, broadening the pipeline. Andrew J. Oakley joins the board.

January 28, 2021 Novaremed

Novaremed secures $50 million capital commitment from GEM

The agreement provides a share subscription facility for 36 months post-public listing. Funds will advance clinical development of NRD135S.E1 for painful diabetic peripheral neuropathy.

December 18, 2020 Novaremed

Novaremed receives FDA Fast Track Designation for NRD135S.E1

The designation facilitates development of NRD135S.E1 for Painful Diabetic Peripheral Neuropathy. Novaremed plans a Phase 2b study.

Media coverage

July 21, 2022 Business Wire

Novaremed signs an exclusive option and license agreement with NeuroFront for the non-opioid neuropathic pain treatment, NRD.E1, for Greater China and Singapore

Novaremed AG and NeuroFront Therapeutics (Hong Kong) Limited have jointly announced the signing of an exclusive collaboration and commercialization agreement for...

March 17, 2022 Yahoo Finanzen

Novaremed concludes exclusive option and license agreement with NeuroFront for non-opioid neuropathic pain treatment NRD.E1 for Greater China and Singapore

NeuroFront receives option on an exclusive license for the development, marketing and manufacturing of NRD.E1, Novaremed's first non-opioid investigational drug for the treatment of chronic neuropathic...

March 17, 2021 Finanznachrichten

Novaremed AG: Novaremed expands its pipeline of non-opioid treatment candidates for chronic pain through the acquisition of Metys Pharmaceuticals

Novaremed AG, a biopharmaceutical private company active in the field of clinical research, announces the acquisition of Metys Pharmaceuticals AG (Metys) with all development programs as part of...

January 28, 2021 Business Wire

Novaremed Secures US $50 Million Capital Commitment from Global Emerging Markets

Novaremed AG (Novaremed), a clinical-stage Swiss biopharmaceutical company, announced today that it has signed an agreement with GEM Global Yield LLC SCS (GE...

Never miss news about Novaremed

Track Novaremed and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Novaremed competitors & trending companies

Browse news for competitors to Novaremed and other trending companies.